Myeloma 2015 | Optimizing proteasome inhibitors for the treatment of multiple myeloma
Robert Orlowski
At the Myeloma 2015 meeting, Prof Robert Orlowski (MD Anderson Cancer Center, Houston, TX) discusses multiple novel proteasome inhibitors in clinical development that have shown promising activity for the treatment of multiple myeloma. Rationally based combination therapies involving proteasome inhibitors may offer a new option to overcome drug resistance.
Related videos

Myeloma XI trial: increased progression-free survival
Charlotte Pawlyn

Pivotal STORM study: selinexor for penta-refractory multiple myeloma
Joshua Richter

Current challenges for multiple myeloma therapy: 2, 3, 4-drug combinations
Joshua Richter

Multiple myeloma musings: highlights from 2018 data
Joshua Richter

An exciting era for CAR T-cell therapy
Mohamad Mohty
More from Robert Orlowski